Minimally invasive coronary bypass with cangrelor
Official title: Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Run by Cardiocentro Ticino · NCT07514962 · Data updated 2026-11-12
This study will try giving a short-acting IV antiplatelet drug (cangrelor) during minimally invasive coronary bypass surgery in adults with coronary artery disease to see if it prevents clots without causing extra bleeding.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Cardiocentro Ticino Academic / other |
| Locations | 1 site (Lugano, Ch/ti) |
| Status | Recruiting |
| Started | May 12, 2024 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | April 14, 2026 |
| Trial ID | NCT07514962 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) scheduled for MIDCAB with an IMA-to-LAD graft who can provide informed consent and have no contraindications to cangrelor are ideal candidates.
✕Probably not a fit
Patients with active bleeding, known bleeding disorders, recent fibrinolytic or GP IIb/IIIa use, severe renal or liver disease, pregnancy, or those undergoing concomitant PCI are unlikely to benefit or be eligible for this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label, single-center case-control study compares adults undergoing MIDCAB who receive a continuous intraoperative cangrelor infusion to historical controls treated with aspirin with or without prior cangrelor bridging. Cangrelor is started preoperatively and titrated using daily platelet function testing (Multiplate®) to reach target inhibition, with surgery performed at least 24 hours after initiation and intraoperative heparin guided by activated clotting time. The study records procedural details, transfusions, chest tube output, ICU stay, biomarkers, and perioperative complications to evaluate safety and feasibility. The design is exploratory and focused on whether intraoperative cangrelor increases bleeding or reduces thrombotic complications compared with historical practice.
Why it matters
Potential benefit: If successful, intraoperative cangrelor could reduce perioperative clotting risk while maintaining acceptable bleeding rates, improving safety and recovery after MIDCAB.
How similar studies have gone: Cangrelor has been used successfully as a short-acting IV antiplatelet bridging agent in PCI and some perioperative settings, but continuous intraoperative infusion specifically during MIDCAB is relatively novel and not widely studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria for the historical control arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique Inclusion criteria for the prospective arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique * Signed informed consent Exclusion criteria for the historical control arm * Administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding Exclusion criteria for the prospective arm * Unconsciousness * Known hypersensitivity to study drug (cangrelor) * Recent administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding
Where it's running
-
Istituto Cardiocentro Ticino
Lugano, Ch/ti, Switzerland Recruiting
Study contacts
- Principal investigator: Marco Valgimigli, Prof. Dr. Med. — Cardiocentro Ticino
- Study coordinator: Marco Valgimigli, Prof Dr Med
- Email: marco.valgimigli@eoc.ch
- Phone: +41 91 811 51 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty
This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.